A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK)and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe COPD Patients.

Trial Profile

A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK)and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe COPD Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top